Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations

Eli Lilly (NYSE:LLY) First Quarter 2025 Results

Key Financial Results

• Revenue: US$12.7b (up 45% from 1Q 2024).
• Net income: US$2.76b (up 23% from 1Q 2024).
• Profit margin: 22% (down from 26% in 1Q 2024).
• EPS: US$3.07 (up from US$2.49 in 1Q 2024).

Our free stock report includes 2 warning signs investors should be aware of before investing in Eli Lilly. Read for free now.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Eli Lilly EPS Misses Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 26%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 6.4% from a week ago.

Risk Analysis

You should learn about the 2 warning signs we've spotted with Eli Lilly (including 1 which is concerning).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.